Company intelligence / Profile preview
Denali Therapeutics Inc.
South San Francisco, California, United Statesdenalitherapeutics.com ↗
- Ownership
- Public · DNLI
- Employees
- ~422
- Development stage
- Phase 2
01
Overview
Denali has multiple programs in clinical development, with tividenofusp alfa (DNL310) for Hunter syndrome receiving FDA Breakthrough Therapy Designation in January 2025. The company is preparing to submit a biologics license application (BLA) in early 2025 and plans commercial launch in late 2025 or early 2026. They are also seeking accelerated approval for DNL126 for Sanfilippo syndrome.
- Therapeutic areas
- ImmunologyRare DiseasesNeurology
- Modalities
- Enzyme replacement therapiesSmall moleculesAntibodiesOligonucleotidesLarge molecules
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $3.4B
- Total revenue
- $3.6M
- Enterprise value
- $2.7B
Beyond the preview
Go deeper on Denali Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Denali Therapeutics Inc..